Log In
BCIQ
Print this Print this
 

raxatrigine (BIIB074) (formerly CNV1014802)

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionState-dependent inhibitor of sodium channel subunit Nav1.7 (SCN9A)
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNa channel blocker; Nav1.7 (SCN9A) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat neuropathic pain; Treat pain associated with lumbosacral radiculopathy; Treat pain associated with trigeminal neuralgia; Treat trigeminal neuralgia
Regulatory Designation U.S. - Orphan Drug (Treat trigeminal neuralgia)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$675.0M

$200.0M

$475.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/12/2015

$675.0M

$200.0M

$475.0M

Get a free BioCentury trial today